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Abstract
Modafinil is a mild psychostimulant with pro-cognitive and antidepressant effects. Unlike many conventional stimulants,
modafinil has little appreciable potential for abuse, making it a promising therapeutic agent for cocaine addiction. The chief
molecular target of modafinil is the dopamine transporter (DAT); however, the mechanistic details underlying modafinil’s
unique effects remain unknown. Recent studies suggest that the conformational effects of a given DAT ligand influence the
magnitude of the ligand’s reinforcing properties. For example, the atypical DAT inhibitors benztropine and GBR12909 do
not share cocaine’s notorious addictive liability, despite having greater binding affinity. Here, we show that the binding
mechanism of modafinil is different than cocaine and similar to other atypical inhibitors. We previously established two
mutations (W84L and D313N) that increase the likelihood that the DAT will adopt an outward-facing conformational state—
these mutations increase the affinity of cocaine-like inhibitors considerably, but have little or opposite effect on atypical
inhibitor binding. Thus, a compound’s WT/mutant affinity ratio can indicate whether the compound preferentially interacts
with a more outward- or inward-facing conformational state. Modafinil displayed affinity ratios similar to those of
benztropine, GBR12909 and bupropion (which lack cocaine-like effects in humans), but far different than those of cocaine,
b-CFT or methylphenidate. Whereas treatment with zinc (known to stabilize an outward-facing transporter state) increased
the affinity of cocaine and methylphenidate two-fold, it had little or no effect on the binding of modafinil, benztropine,
bupropion or GBR12909. Additionally, computational modeling of inhibitor binding indicated that while b-CFT and
methylphenidate stabilize an ‘‘open-to-out’’ conformation, binding of either modafinil or bupropion gives rise to a more
closed conformation. Our findings highlight a mechanistic difference between modafinil and cocaine-like stimulants and
further demonstrate that the conformational effects of a given DAT inhibitor influence its phenomenological effects.
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Introduction
Modafinil (2-(benzhydrylsulfinyl)acetamide) is a mild psycho-
stimulant-like agent that increases wakefulness, improves attention
and enhances performance in a variety of cognitive tasks [1–3].
Modafinil has been shown to exert antidepressive effects [4] and
like other stimulants is an effective adjuvant for those experiencing
only marginal improvement with serotonergic compounds [5,6].
Classical psychostimulants, such as dextroamphetamine and
methylphenidate exhibit dose-dependent biphasic effects on
cognition—enhancing performance, learning and memory con-
solidation at moderate doses, but impairing cognitive function
when used at high doses [7–9]. From a phenomenological
perspective, modafinil has nootropic (pro-cognitive) effects similar
to those of low-dose classical psychostimulants. However,
compared to typical stimulants, modafinil possess a far more
subtle and benign pharmacological profile [10]. Modafinil appears
to lack many of the undesirable side effects of other stimulants,
most notably: cardiovascular strain, sympathomimetic peripheral
stimulation and significant addictive liability [11]. As such,
modafinil has shown considerable promise as a therapeutic in
the treatment of addiction to cocaine, one of the most frequently-
used recreational drugs and likely the most addictive, based upon
the percentage of both initial and regular users that transition into
severe addicts [12,13]. Modafinil attenuates craving for cocaine
during drug withdrawal and has also been shown to decrease self-
administration of smoked cocaine base (crack) in habitual crack
users [14,15]. Importantly, a recent study of modafinil self-
administration in human cocaine addicts demonstrated that
modafinil was not administered more frequently than placebo,
nor did it occasion cocaine-like subjective effects [16].
The pharmacodynamic mechanism of modafinil is rather poorly
understood and a wide-ranging variety of neurochemical systems
have been previously implicated in its activity (for review, see e.g.
[17]). One of the most prominent unresolved questions regarding
modafinil’s mechanism of action is: why does it lack the notable
addictive potential of classical stimulants, such as cocaine? An
understanding of why modafinil has a far lower abuse liability than
prototypical stimulants may facilitate the design of novel and
improved stimulant therapeutics for ADHD, cognitive enhance-
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question, however, one must first possess insight into the protein
target(s) of modafinil in the brain. Zolkowska et al. (2009) recently
performed a ‘‘receptorome’’ screen, examining the interaction of
modafinil with a large array of different neuronal receptor and
transporter proteins in vitro [18]. Of the included receptor
proteins, the neuronal dopamine transporter (DAT) was the sole
target at which modafinil displayed relevant binding (that is, the
only protein for which it possessed a Ki value lower than the
threshold of 10 mM). However, the addictive stimulants cocaine
and methylphenidate also principally target the DAT. What makes
modafinil different? One enigmatic aspect of DAT pharmacology
is the disparate reinforcing efficacy of various transporter ligands.
A particular DAT-inhibiting molecule may have dramatic, mild or
even a complete lack of behaviorally rewarding effects, regardless
of absolute binding affinity [19,20]. In this sense, the DAT appears
to behave somewhat like a classically defined receptor, in that
interaction with chemically distinctive ligands can elicit different
behavioral effects in vivo. Recently, different chemical classes of
ligands have been shown to stabilize the transporter protein in
distinct conformational states upon binding; moreover, interaction
with a specific conformation has been posited to affect the
‘‘addictiveness’’ of a given ligand [21]. It is important to note that
rate of onset has also been shown to affect the addictiveness of
DAT ligands—compounds with a rapid onset of action tend to
exhibit greater reinforcing efficacy than those with a slower onset
rate [22–25]. Compared to cocaine, modafinil has a slower onset
of action [26]; hence, it is possible that this characteristic also
contributes to its low addictive liability.
The specific molecular mechanism underlying the DAT’s
substrate translocation cycle is not known. However, high-
resolution crystallographic structures of a related transporter
protein—a leucine transporter from the bacterium Aquifex aeolicus
(LeuT)—bound to a variety of substrate-like and inhibitor-like
ligands [27–29] provided a groundbreaking template for in silico
molecular modeling of DAT ligand-binding dynamics [30,31].
LeuT is a prokaryotic member of the neurotransmitter/sodium
symporter (NSS) family of proteins, which also includes the
eukaryotic transporters for serotonin, noradrenaline and dopa-
mine (SERT, NET and DAT, respectively). The crystal structures,
combined with a plethora of additional investigations of LeuT
binding kinetics [32,33] and single-molecule dynamics [34,35]
suggest an alternating access translocation cycle with at least three
dominant low-energy conformational states (depicted in Fig. 1).
The substrate interaction pocket at the center of the 12
transmembrane domain (TM) transporter protein (referred to as
the ‘S1’ or primary substrate site) can be occluded from solution by
both intra- and extracellular gating networks. These gates are
formed by a small number of critical residue side-chains (highly-
conserved throughout the NSS family), via networks of ionic, p-
cation and hydrogen-bonding interactions [36]. Disruption and
reformation of these interaction networks—mediated by the
binding of ions and substrate or other ligands [34]—likely
underlies the alternating access mechanism, allowing transition
between terminal ‘‘open-to-out’’ (outward-facing) and ‘‘open-to-
in’’ (inward-facing) conformations, with a dually occluded
intermediate. Further studies with LeuT have revealed the
presence an additional substrate-binding domain (dubbed the
‘S2’ site) located in the extracellular vestibule of the transporter,
11–13 A ˚ above the central S1 site. This vestibular site appears to
bind a variety of different ligands, including a second molecule of
the substrate leucine [32], alkylglucoside detergents [37] and a
Figure 1. Cartoon representation of the DAT alternating access conformational cycle. (A) A fully outward-facing conformation with an
open extracellular gating network (open-to-out) is established by binding of Na
+ at the S1 site and is therefore the predominant state in the presence
of high extracellular Na
+ levels and absence of substrate. (B) Following Na
+ binding, substrate interaction with S1 site residues triggers closure of the
extracellular gate, establishing an occluded (closed-to-out) intermediate conformation. (C) Putative interaction of a second molecule of substrate
with the vestibular S2 site helps facilitate opening of the intracellular gating network, giving rise to a fully inward-facing (open-to-in) conformation
capable of releasing S1-bound substrate and ions into the cytoplasm.
doi:10.1371/journal.pone.0025790.g001
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SSRIs like fluoxetine and sertraline [39]. Interestingly, whereas
tricyclics and other inhibitors that bind at the S2 site stabilize
LeuT in an occluded state, binding of the competitive inhibitor
tryptophan (which binds at the S1 site, displacing leucine itself)
stabilizes an open-to-out conformational state [29].
Mutagenesis and cysteine-accessibility studies suggest that
cocaine and structural analogues preferentially stabilize the DAT
in the open-to-out conformation [40,41]. In contrast, atypical
inhibitors—compounds that potently inhibit the DAT, yet do not
share cocaine’s abuse potential (such as benztropine, GBR12909
and bupropion)—stabilize a ‘‘closed-to-out’’ conformation; that is,
either an occluded or inward-facing state [21,42]. Here, we
present evidence that modafinil displays atypical-like binding
characteristics—stabilizing the DAT in a different conformation
than cocaine-like compounds. We have previously characterized
two DAT mutations (W84L and D313N) that disrupt the
transition between outward- and inward-facing states, increasing
the likelihood that the transporter will adopt an outward-facing
conformation [43]. These mutations considerably increase the
affinity of cocaine-like inhibitors as measured by inhibition of
[
3H]CFT binding, but have negligible or opposing effects on the
affinity of atypical inhibitors [42,44]. Thus, a given DAT ligand’s
affinity ratio at mutant versus WT transporters can offer insight
into whether the ligand preferentially interacts with the outward-
or the inward-facing conformational state. We employed these
mutants, as well as conformation-biasing ionic conditions [45], to
investigate the binding mechanism of modafinil at the DAT.
Additionally, we performed in silico induced-fit docking of the
atypical inhibitors modafinil and bupropion and the cocaine-like
inhibitors b-CFT and methylphenidate, in order to probe possible
structural differences in DAT interaction between the two classes
of compounds.
Materials and Methods
Generation of cell lines stably expressing WT and mutant
DATs
In this work, we used Human Embryonic Kidney cells
(HEK293) stably expressing WT human DAT, or the human
DAT mutants W84L or D313N. HEK cells were obtained from
ATCC (ATCC CRL 1573) as previously described; transfected
cell lines were prepared by us for studies previously reported
[43,44]. Human DAT mutant plasmids were generated using site-
directed mutagenesis as previously outlined [43]. Mutations were
screened by PCR and restriction enzyme mapping. The cells were
stably transfected with the various DAT plasmids using Lipofecta-
mine (Invitrogen, Carlsbad, CA, USA) and were maintained with
,250 mM geneticin (G418).
[
3H]CFT binding inhibition assays
For binding assays, suspensions of intact HEK-hDAT were
prepared according to the method outlined previously [42,44].
Cell slurry was incubated for 1 hr at 21uC and centrifuged; the
supernatant was discarded and the subsequent pellet was washed
and gently resuspended in 6 mL KRH buffer solution in
preparation for assay. Modified Krebs/Ringer/HEPES (KRH)
buffer containing 1 mM ascorbic acid and 0.1 mM tropolone was
used. In the ‘sodium free’ binding conditions, buffer NaCl was
isotonically replaced with N-methyl-D-glucamine chloride
(NMDG-Cl). For zinc-modulated binding conditions, 10 mM
Zn
2+ was added to the assay buffer before the addition of the
unlabeled test ligand and [
3H]CFT. Assays were conducted in 96-
well plates at 21uC, with all determinations performed in triplicate
wells. Binding reactions were initiated by addition of 50 mL cell
suspension to buffer containing radioligand and varying concen-
trations of test ligand, for a final per-well reaction volume of
200 mL. Cells were incubated with 2–4 nM [
3H]CFT (85.9 Ci/
mmol) and test compounds for 15 min at 21uC. Nonspecific
binding was determined using 1 mM non-radiolabeled b-CFT.
Binding was terminated by vacuum filtration onto a filtermat
(Wallac A) and washing with 0.9% ice-cold saline using a Tomtec
automatic 96-pin cell harvester (Tomtec, Orange, CT, USA).
Tritium accumulation was quantified using a Microbeta 1405
liquid scintillation counter (Perkin-Elmer, Boston, MA, USA).
Data analysis and statistics
Kinetic parameters, such as the equilibrium dissociation
constant of radioligand binding (KD), were determined by
respective competition analysis with non-radiolabeled b-CFT,
using Kell RADLIG (Biosoft, Cambridge, UK). For each tested
DAT ligand, the IC50 for inhibition of [
3H]CFT binding was
calculated with Origin 7.5. IC50 values for the DAT ligands were
converted into relative inhibition constants (Ki) using the Cheng-
Prusoff equation [46].
Homology modeling and flexible docking
The DAT protein homology model was generated in a manner
similar to the procedure detailed in Schmitt et al. (2010) [47]. The
crystal structure of LeuT bound to the ligands leucine and the
tricyclic antidepressant (TCA) desipramine ([28]; PDB Index
2QJU) was used as the structural template, employing the NSS-
family protein amino acid sequence alignment proposed by
Beuming et al. (2006) [48]. Since the sequence of LeuT is shorter
than that of the DAT, parts of the intracellular termini were
excluded from the model (N-terminal residues M1-V55 and
residues K589-V620 on the C-terminus). In addition, all water and
b-octylglucoside molecules and the ligands present in the template
LeuT crystal were not included in the DAT model. The sodium
ions were initially placed in the DAT model based upon their
location in LeuT, but were allowed to move freely during energy
minimization, docking and optimization rounds. The DAT
chloride ion was initially placed at the position corresponding to
E290 in the LeuT structure (in the DAT, this residue is S357—the
negative charge provided by glutamate renders LeuT Cl
2-
insensitive) [49,50].
Homology modeling was performed using the MODELLER
algorithm and the resultant lowest energy structure was imported
into the Molecular Operating Environment (MOE) program suite
(Version 2009.10; Chemical Computing Group, Montreal, CA).
The Protonate3D function in MOE was used to calculate residue
protonation states and assign hydrogen atom coordinates; partial
charges were assigned according to the AMBER99 forcefield. In
order to refine residue stereochemistry and relieve any steric
clashes in the protein prior to ligand docking, the DAT model was
subjected to several rounds of energy minimization, employing the
AMBER99 forcefield and the generalized Born (GB/VI) implicit
solvation model [51]. During the first round, protein backbone
atoms were dynamic and the model was minimized until hitting a
convergence gradient of 0.05 kcal mol
21 A ˚ 21. Subsequent mini-
mization rounds focused on optimizing side chain geometry of
particular residues, hence backbone atoms were tethered and a
more stringent convergence value (0.001 kcal mol
21 A ˚ 21) was
employed. Analysis of the final DAT model with PROCHECK
[52] indicated that 98.9% of the residues fell within either the
‘most favored’ or ‘additionally allowed’ Ramachandran plot
region (86.8% most favored); only four residues (0.9%) fell within
the ‘generously allowed’ region and only one residue (Q373; 0.2%)
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of model stereochemical quality, see [47]).
Ligand binding sites in the DAT model were identified with the
Site Finder tool implemented in MOE—after manual elimination
of sites lying directly on the exterior, cytoplasmic or extracellular
faces of the protein, two binding pockets (approximately
overlapping with the S1 and S2 sites of LeuT) were identified.
Dummy atoms were placed at the centroids of alpha spheres
defining these two sites to assist in ligand docking. For docking,
ligand structures were imported into MOE, protonated, assigned
partial charges and energy minimized (,0.001 kcal mol
21 A ˚ 21)
using the MMFF94x forcefield with GB/VI implicit solvation. In
the preliminary docking process, ligand bond length and DAT
protein atoms are held constant and various ligand orientations
and conformational rotomers are systematically positioned in the
active site such that no steric clashes between ligand and residue
side-chains occur. The top 50 non-duplicate docked poses
(London dG scoring method) were output to a MOE database
and manually sorted into two population clusters, representative of
binding at either the central S1 site (below the R85-D476 gating
interaction) or the vestibular S2 site (above the R85-D476 gate).
Examples of S1-localized highly-populated ‘‘metapose’’ clusters
are shown in the Supporting Information (Fig. S1). An
energetically favorable (top-scoring) pose from each population
was chosen as a representative for ligand-adaptive geometric
optimization; however, poses that did not display any strong
molecular interactions (e.g. hydrogen bonds, cation-p and aromatic
p-stacking interactions) with specific residues within their binding
pocket were not considered.
Representative poses were then refined by further minimization
of the protein/ligand. In refinement rounds, protein backbone
atoms were weakly tethered (1 kcal mol
21 A ˚ 21 force constant)
and the side-chain and ligand atoms completely unconstrained to
allow for flexible ‘‘ligand adaptive’’ docking—for the last
minimization round, the backbone tethering constant was
increased to 10 kcal mol
21 A ˚ 21 and the convergence gradient
was set at 0.01 kcal mol
21 A ˚ 21. Final ray-traced models depicted
in figures were rendered with PyMOL 1.4 (Schro ¨dinger LLC, New
York, NY, USA). All MOE simulations were performed on a
standard quad-core 664 computer running Windows 7.
Results
Binding and mutant affinity-shift profile of modafinil and
DAT inhibitors
Modafinil and other compounds—representing different chem-
ical classes of DAT ligands (Fig. 2)—were assayed for their ability
to inhibit [
3H]CFT binding to WT or mutant DATs expressed in
whole HEK293 cells. The binding affinities (Ki values) of the tested
compounds and the observed WT/mutant affinity ratios are listed
in Table 1. Modafinil’s binding affinity at WT transporters was
relatively low (Ki=2.1 mM); compared to the other reference
ligands, modafinil was anywhere from 6- to 100-fold weaker
(Table 1). The micromolar level affinity is consistent with prior
literature reports of modafinil radioligand binding at the DAT and
likely underlies the comparatively high effective dose of modafinil
(200–600 mg) in humans [18,53]. At the W84L mutant, modafinil
showed a significant decrease in affinity (an increase in Ki value to
3.8 mM; p,0.05) compared with the WT transporter, resulting in
a WT/W84L Ki ratio of 0.56 (Table 1). This mutant affinity-shift
was strikingly similar to that observed with the atypical ligands
benztropine, GBR12909 and bupropion (for each of these ligands,
the WT/W84L Ki ratio was approximately 0.5). In contrast, the
classical DAT inhibitors cocaine, b-CFT and methylphenidate all
showed significantly increased binding affinity (decreased Ki value)
at the W84L mutant: the tropane compounds both gave 3.5-fold
improvements, whereas methylphenidate displayed a more modest
2-fold gain. At the D313N mutant, modafinil showed little change
in affinity compared with WT (having a WT/D313N Ki ratio of
0.95), behaving similarly to bupropion and GBR12909—which
gave WT/D313N Ki ratios of 0.90 and 1.05, respectively—but not
to any of the cocaine-like ligands (Table 1).
Figure 2. Chemical structures of modafinil and other tested DAT inhibitor ligands. Atypical inhibitors (top row) exhibited preferential
interaction with a more inward-facing transporter conformation, whereas cocaine-like inhibitors (bottom row) preferentially bound to the outward-
facing DAT conformation. While modafinil has a chiral sulfoxide moiety, the enantiomers possess little difference in pharmacodynamic activity (hence,
only the racemate was tested).
doi:10.1371/journal.pone.0025790.g002
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modafinil and DAT inhibitor binding
Various endogenous ionic species are known affect the
conformational equilibrium of the DAT and other NSS-family
proteins. For example, recent biophysical studies with LeuT have
demonstrated that binding of Na
+ to the substrate-free (apo) form
of the transporter induces a conformational shift toward the open-
to-out state, increasing accessibility of the extracellular vestibule
[34] and constricting residues near the intracellular gating network
[35,54]. The sodium gradient present under normal physiological
conditions (high extracellular Na
+ concentration and low intra-
cellular Na
+ concentration) therefore gives rise to a population of
transporters that are predominantly outward-facing, primed to
bind ligands approaching from the extracellular milieu [55]. In the
absence of significant sodium levels, the transporter effectively
shifts between outward and inward-facing conformations [35].
Hence, changing the ionic conditions by removing extracellular
sodium (without grossly altering intracellular ionic components)
would be expected to increase the preponderance of a ‘‘closed-to-
out’’ state amongst the overall population of transporters.
Applying this logic to the DAT, we performed intact-cell binding
assays with buffer Na
+ isotonically substituted for the inert and
membrane-impermeant cation NMDG
+ (yielding a functionally
0 mM concentration of extracellular Na
+ without significantly
affecting intracellular ionic conditions), a treatment previously
demonstrated to increase the relative number of inward-facing
DATs [56]. Replacement of buffer sodium resulted in a decrease
of affinity (increase in Ki value) for all of the tested DAT inhibitors
(compare Ki values of WT transporter in Table 1 to those of the
Na
+-Free condition listed in Table 2). However, amongst the
inhibitors, modafinil and GBR12909 were least impacted by
sodium depletion, displaying 1.4- and 1.8-fold increases in
respective Ki values.
Zinc is another important endogenous modulator of the DAT;
in vivo, it forms organometallic coordinations with three residues at
the top of the extracellular vestibule of the transporter (H193,
H375 and E396). By loosely ‘‘grasping’’ these three residues on the
external protein face, zinc likely impedes the transition between
outward- and inward-facing conformations, biasing the equilibri-
um in favor of the outward-facing state [41]. Effects of
exogenously-applied Zn
2+ are observable experimentally at
micromolar concentrations: Zn
2+ increases the binding of b-CFT
and cocaine [44,45] and can partially overcome the effects of DAT
mutations exerting an inward-facing conformational bias (the
opposite of the W84L or D313N mutations), such as the Y335A
[41], D345N [57] and W267L [58] mutants. We thus used Zn
2+ to
investigate the conformational preference of modafinil and the
other DAT ligands. By increasing the population of outward-
facing DATs and (at least partially) reversing the effect of
extracellular Na
+ depletion, zinc can highlight compounds that
Table 1. Potencies of modafinil and other DAT inhibitors, assessed by displacement of intact-cell [
3H]CFT binding to WT or mutant
hDAT.
Compound Whole-Cell hDAT Binding Ki (nM) Ki [WT]/Ki [Mutant] Ratio
WT W84L D313N WT/W84L WT/D313N
b-CFT 15.462.1 4.4460.69* 6.1460.29* 3.47 2.51
(2)-cocaine 163.661.20 46.764.52* 51.565.06* 3.50 3.18
(6)-methylphenidate 21.263.7 11.161.6* 11.460.38* 1.91 1.86
benztropine 75.367.4 189.566.82* 181.4630.3* 0.40 0.42
(6)-bupropion 319.5624.9 745.9614.0* 353.9616.7 0.43 0.90
GBR12909 53.2619.7 108610.7* 50.661.2 0.49 1.05
(6)-modafinil 21436215 38166266* 22556229 0.56 0.95
Binding assays were performed using intact stably-transfected HEK293 cells; values are means 6 SEM for 3–6 experiments, each performed in triplicate.
*Significant difference versus wild-type binding affinity (p,0.05; t test, two-tailed). Data for inhibitors other than modafinil included from [42] for reference.
doi:10.1371/journal.pone.0025790.t001
Table 2. [
3H]CFT binding potency of modafinil and other DAT ligands in the absence of extracellular Na
+ and the effect of Zn
2+ on
binding affinity.
Compound Whole-Cell WT hDAT Binding Ki (nM) Zn
2+ Effect Ratio
Na
+-Free (0 mM) Buffer Na
+-Free+10 mMZ n
2+ Ki [0 mM]/Ki [10 mM]
(2)-cocaine 415.3641.1 229.2627.7* 1.81
(6)-methylphenidate 252.9624.1 98.9268.94* 2.56
benztropine 231.1617.0 209.9618.1 1.10
(6)-bupropion 709.3665.3 737.1655.4 0.96
GBR12909 95.9968.74 126.8615.6 0.76
(6)-modafinil 29636161 34706261 0.85
Assays were performed in Na
+-free conditions (buffer sodium was isotonically replaced with the impermeant cation NMDG
+) in the presence and absence of 10
micromolar zinc; values are means 6 SEM for 3–7 experiments, each performed in triplicate.
*Significant difference versus Na
+-Free affinity value (p,0.05; t test, two-tailed).
doi:10.1371/journal.pone.0025790.t002
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buffer conditions, the addition of 10 mMZ n
2+ significantly
increased the binding affinity (decreased the Ki value) of cocaine
and methylphenidate at WT transporters (Table 2). For inhibition
of [
3H]CFT binding by cold b-CFT, the presence of Zn
2+ under
sodium-free conditions increased the Bmax value of labeled
[
3H]CFT by a factor of four, from 125615.8 fmole/well to
502678 fmole/well. The calculated absolute Kd values for the
sodium-free and +10 mMZ n
2+ conditions were not significantly
different: 49.3269.69 and 57.0866.67, respectively. This zinc-
mediated effect—alteration in the Bmax, but not the Kd kinetic
parameter—has been demonstrated before in both Na
+-free [58]
and physionormal Na
+ (130 mM) buffers [45,59]. It is likely that
the particular kinetic effects of micromolar Zn
2+-levels depend on
the specific assay protocol and nonlinear curve-fitting algorithm
used. Addition of Zn
2+, however, had little impact on the atypical
DAT inhibitors overall (the ratio of Ki values obtained in the
absence and presence of zinc was close to unity for each
compound; Table 2). This finding suggests that unlike b-CFT,
cocaine or methylphenidate, the interaction of modafinil (like
GBR12909, benztropine and bupropion) with the DAT is far less
dependent on the transporter assuming an open-to-out conforma-
tional state.
Adaptive docking of modafinil and other inhibitors in an
hDAT model
In an attempt to gain structural insight into the differential
interactions of cocaine and modafinil with the DAT, we employed
a homology model of the human DAT and docked (R)-modafinil,
as well as (S)-bupropion, (d)-methylphenidate and b-CFT with a
flexible ligand-adaptive docking procedure. Specific enantiomers
of the various DAT inhibitors were used in order to simplify the
docking protocol. The (S)-enantiomer of bupropion was selected
based upon the stereoselective dopaminergic activity of its primary
metabolite (S,S)-hydroxybupropion [60] and the comparatively
greater isomeric potency of other (S)-cathinones [61,62]. Dex-
methylphenidate (the threo-(R,R)-isomer of methylphenidate) has
been extensively shown to be wholly responsible for the DAT-
mediated physiological effects of the racemate [63,64] and was
therefore selected for modeling. The stereochemistry of modafinil
differs from other DAT ligands, as modafinil’s stereocenter is not
the typical asymmetric carbon atom, but a sulfinyl moiety (Fig. 2).
Unlike other DAT ligands, which generally possess significant
enantioselectivity, (R)- and (S)-modafinil show only mild differences
in DAT affinity, with the (R)-enantiomer having marginally
greater affinity [65]. In humans, racemic modafinil and (R)-
modafinil are active at similar doses, but the (R)-isomer has a more
stable pharmacokinetic profile [66] and was recently released to
the market as an enantiopure drug (armodafinil); hence, it was
selected as the more ‘‘active’’ isomer for docking. b-CFT was
chosen over cocaine for its structural rigidity, as flexibility
imparted by cocaine’s benzoyloxy moiety prevented the docking
procedure from converging upon particularly consistent pose
clusters. The hDAT model was based upon the structure of LeuT
co-crystallized with its substrate leucine, as well as the tricyclic
antidepressant desipramine [28]. We previously employed this
DAT model in docking of substrates and bivalent substrate-like
inhibitors [47]. Two ligand-binding pockets identified in the
hDAT model were used for docking—roughly corresponding with
the S1 and S2 sites of LeuT—and each inhibitor was docked in
both sites. A single candidate was selected from a cluster of top-
scoring poses and used as the initial input for further energy
minimization of the protein/ligand complex (see Fig. S1 for
examples of pose clusters from which potential candidates were
selected).
Following docking at the S1 site, modafinil was oriented
horizontally (parallel to the plane of the membrane), with the
diphenyl ring system facing V152, G153 and Y156 of TM3 and
the sulfinylacetamide chain surrounded by F76, A77, D79 of TM1
and F320, S321 and L322 of TM6 (Fig. 3A). In this pose, few
strong molecular interactions between modafinil and the DAT
were observed, save for hydrogen bonds formed between
modafinil’s terminal amide nitrogen and residues F76, A77 and
D79 (Fig. 4A). At the S2 site, modafinil was positioned just above
the extracellular vestibule gating residues R85, F320 and D476
(Fig. 3B); one phenyl ring formed a cation-p interaction with R85
and the protonated amide displayed a combination of hydrogen
bonding with D476 and a cation-p interaction with the aromatic
side chain of F320 (Fig. 4B). Bupropion docked at a slightly lower
position in S1 (Fig. 3C), but like modafinil, the aromatic portion of
the molecule was oriented parallel to V152 and enveloped by
residues of TM3, whereas the amine nitrogen and bulky tert-butyl
group were oriented towards D79, F320 and other adjacent
residues of TMs 1 and 6 (Fig. 4C). In the S2 site, while bupropion
was positioned marginally higher than modafinil in the extracel-
lular vestibule (Fig. 3D), its strongest molecular interactions—a
cation-p interaction with R85 and a hydrogen bond between the
amine and D476—were similar (Fig. 4D).
The cocaine-like inhibitors b-CFT and d-methylphenidate also
yielded highly populated pose clusters when docked in the S1 and
S2 sites (a representative pose cluster for CFT docked at the S1 site
is shown in Fig. S1B). At the S1 site, the tropane amine of CFT
engaged in hydrogen bonding with D79, with the N-methyl group
oriented downward towards F76 and neighboring residues in TMs
1 and 6 (Fig. 5A). The tropane ethylene bridge was directed
upward toward the extracellular gate, likely blocking the aromatic
side chain of F320 from establishing an interaction with the
cationic nitrogen. In addition, the 3b-fluorophenyl ring of CFT
participated in p-p stacking aromatic interaction with the side-
chain of F326 and the 2b-carbomethoxy moiety formed a
hydrogen bond with S422 of TM8 (Figs. 5A and 6A). Many of
the interactions and binding pocket residues found for CFT were
consonant with those reported in prior molecular simulations of
phenyltropane binding at the S1 site (e.g. [31]). In the S2 site, CFT
was oriented perpendicular to the plane of the membrane, with the
charged tropane amine directed towards the top of the
extracellular vestibule (Fig. 5B). Residues from extracellular loop
4 (D385, G386 and P387) helped to shield CFT from the
extracellular space, with the backbone of D385 forming a
hydrogen bond with the tropane nitrogen (Fig. 6B). The 2b-
carbomethyoxy moiety was situated directly adjacent to the side-
chains of R85, F155 and D476, but did not disrupt the interaction
between R85 and D476. In contrast to the other DAT inhibitors
docked in the S2 site, the aromatic portion of CFT dipped below
the R85-D476 extracellular gate (Fig. 5B), enabling a p-p stacking
interaction between the S1-localized residue Y156 and the 3b-
fluorophenyl substituent (Fig. 6B). This binding orientation is
relatively consistent with other computational studies modeling
cocaine and phenyltropane binding in the extracellular vestibule
(S2 site) of the dopamine and noradrenaline transporters in the
presence of respective substrates bound at S1 [67,68].
Despite adopting a slightly different orientation, we found that
d-methylphenidate shared many of the same interactions and
binding pocket residues with b-CFT when docked at the S1 site
(Fig. 5C). In particular, the methyl ester moiety of methylpheni-
date engaged in hydrogen bonding with the side-chain of S422
and the cationic amine formed a bond with D79 (Fig. 6C). The
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involved F320: for methylphenidate, the charged piperidine amine
group formed both a cation-p interaction with the aromatic side-
chain of F320 and a hydrogen bond with the backbone. However,
at the S2 site, methylphenidate exhibited an interaction pattern
and binding orientation more akin to that of modafinil—forming a
cation-p interaction between the ligand aromatic ring and R85,
with the protonated ligand amine anchored by a combination of
hydrogen bonding with D476 and a cation-p interaction with the
aromatic side chain of F320 (Figs. 5D and 6D).
Our in silico modeling data are also consistent with the idea that
modafinil interacts with the DAT in a different manner than
cocaine-like inhibitors. In a recent study combining molecular
simulation and site-directed mutagenesis, Beuming et al. (2008)
showed that the presence or absence of a hydrogen bond between
D79 and Y156 in a given DAT/ligand complex can provide an
indication of the conformational bias engendered by the ligand
[31]. The highly conserved TM3 tyrosine residue Y156 interacts
with the substrate dopamine as it binds at the S1 site and also
participates in the vestibular gating network—consisting of R85,
F320 and D476—that partitions the S1 and S2 sites [69,70].
When dopamine is bound at the S1 site, a hydrogen bond formed
between the side chain oxygen atoms of D79 and the hydroxyl
moiety of Y156 helps to close the extracellular gate, protecting the
S1-bound substrate from infiltration by water from the extracel-
lular space [31]. Hence, the presence of a D79-Y156 hydrogen
bond is associated with a ‘‘closed-to-out’’ transporter state. In their
molecular dynamics simulations, Beuming et al. (2008) showed that
an interatomic distance of less than 3.5 A ˚ (indicative of an intact
hydrogen bond) was maintained between the oxygen atoms of D79
and Y156 during binding of DAT substrates (dopamine,
amphetamine and MDMA) in the S1 site. In contrast, binding
of the classical inhibitors b-CFT and cocaine yielded D79-Y156
distances greater than the 3.5 A ˚ maximum for hydrogen bonding
(<5.5 A ˚ and <7.5 A ˚, respectively), signifying an open vestibular
gate in each case. Binding of the atypical inhibitor benztropine,
however, resulted in a preserved D79-Y156 hydrogen bond (i.e. an
interatomic distance less than 3.5 A ˚), suggesting that—unlike
cocaine—binding of benztropine at the S1 site does not prevent
closure of the gate.
In an effort to expand upon this finding, we measured the
terminal D79-Y156 distance for each of the modeled DAT
inhibitors when bound at either the S1 or the S2 site (Figs. 3 and 4,
distance values are indicated in yellow at the bottom of each
panel). Modafinil docked at the S1 and S2 sites yielded respective
D79-Y156 distances of 2.29 A ˚ and 2.25 A ˚ (Fig. 3A–B), suggesting
Figure 3. Final energy-minimized poses of atypical inhibitors docked at the DAT primary (S1) and vestibular (S2) substrate binding
sites. Selected binding pocket residues are labeled and rendered as sticks; bound ligand molecules (also shown as sticks) are highlighted using gray-
colored carbon atoms. The distance between the carboxylate oxygen atom of D79 and the ring hydroxyl moiety of Y156 is displayed in the lower
right of each panel (in yellow). (A, B)( R)-modafinil docked at the S1 and S2 sites, respectively—at the S1 site (A), modafinil primarily interacts with
D79 and adjacent TM1 residues, whereas at the S2 site (B), it mainly interacts with residues that form the extracellular gating network. (C, D)( S)-
bupropion docked at both the S1 (C) and S2 sites (D). Note that for each of the DAT/inhibitor models, the bound inhibitor molecule does not disrupt
the D79-Y156 hydrogen bond (i.e. the interatomic distance remains less than 3.5 A ˚ following adaptive docking procedures).
doi:10.1371/journal.pone.0025790.g003
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network. Similarly, the atypical inhibitor bupropion gave respec-
tive interatomic distances of 2.34 A ˚ and 2.37 A ˚ when docked at
the S1 and S2 sites (Fig. 3C–D). In accordance with the findings of
Beuming et al. (2008), docking of b-CFT at the S1 site resulted in a
D79-Y156 distance of 4.85 A ˚, indicative of an open extracellular
gate (Fig. 5A). Interestingly, at the S2 site, extension of CFT’s 3b-
fluorophenyl moiety downward into the S1 site permitted an
aromatic stacking interaction with Y156, pushing the tyrosine ring
aside and expanding the D79-Y156 distance to 4.94 A ˚ (Fig. 5B). In
addition, the classical inhibitor d-methylphenidate also disrupted
the D79-Y156 hydrogen bond, yielding S1- and S2-bound
distances of 4.12 A ˚ and 3.57 A ˚, respectively (Fig. 5C–D). This
suggests that cocaine-like phenyltropane inhibitors and methyl-
phenidate are capable of inducing an open-to-out transporter
conformation upon binding at either the S2 or S1 site.
Discussion
The stimulant and nootropic compound modafinil was initially
assumed not to possess a dopaminergic mechanism of action, due
to its structural dissimilarity to other DAT ligands and its relatively
low micromolar-level affinity for the DAT [71]. However, recent
broad-spectrum receptor screening assays have identified the DAT
as the only protein target displaying significant (,10 mM) affinity
for modafinil (although Madras et al. (2006) showed that modafinil
also inhibits noradrenaline uptake by the NET, albeit with an IC50
value of <36 mM) [53]. This is consistent with our finding that
modafinil inhibits [
3H]CFT binding to human DAT with
relatively low affinity (Ki=2.1 mM). Despite its modest affinity,
recent findings that modafinil occupies brain DATs in humans at
clinically-relevant doses—and, like any DAT inhibitor, causes an
increase in extraneuronal dopamine—have prompted some to
Figure 4. Molecular interaction diagrams of docked atypical inhibitors. For each panel, the interaction map depicts DAT residues located
within 4.5 A ˚ of the bound inhibitor molecule (hydrophobic residues are colored green and polar residues are purple). The most significant (non van
der Waals) DAT/ligand interactions are indicated with dotted lines and a symbol depicting the chemistry of the interaction formed: side-chain
hydrogen bond (green), main-chain hydrogen bond (blue), cation-p bond ({+) or aromatic p-stacking ({{). (A, B) Residue interaction maps for
modafinil bound at the S1 (A) and S2 sites (B). (C, D) Interaction maps for bupropion bound at the S1 (C) and S2 sites (D), respectively. For both of
the atypical inhibitors, binding at the S1 site (panels A and C) gives rise to few strong interactions with the DAT—only their protonated nitrogen
atoms form hydrogen bonds—suggesting that recognition of these relatively modest inhibitors (Ki.100 nM) is influenced more by molecular shape
and steric bulk than by specific polar interactions.
doi:10.1371/journal.pone.0025790.g004
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to that of traditional cocaine-like DAT inhibitors (e.g. [72]). In
addition, while certain behavioral studies in animals have shown
that modafinil is not self-administered via the IV route and does
not induce place preference [73,74], others have found that high
doses of modafinil fully substitute for cocaine in drug discrimina-
tion tests [75,76] and that modafinil occasions conditioned place
preference and cocaine-like locomotor sensitization in mice [77].
Clinical and preclinical studies, however, suggest that modafinil
neither elicits stimulant-like subjective effects nor encourages self-
administration in frequent cocaine users [16], unlike the classical
dopamine uptake inhibitor methylphenidate [78]. And while it is
widely accepted that interaction with the DAT underlies cocaine’s
strong addictive potential, extensive research has shown that a
number of atypical DAT inhibitors—such as benztropine,
GBR12909 and bupropion—have limited reinforcing effects in
humans [19,79,80], despite fully substituting for cocaine in animal
drug discrimination protocols (e.g. [76,81]). Moreover, numerous
animal studies have shown that exceptionally potent and selective
DAT inhibitors derived from benztropine or GBR12909 incom-
pletely substitute for cocaine in drug discrimination tests and also
decrease cocaine self-administration [82–85]. As benztropine is
also a potent antagonist at muscarinic M1 and histamine H1
receptors, some have argued that activity at these targets (as
opposed to the DAT itself) underlies benztropine’s low addictive
liability. However, antihistaminergic and antimuscarinic com-
pounds do not attenuate the reinforcing effects of cocaine [86,87].
Additionally, benztropine analogues with lower affinity for the M1
muscarinic receptor than benztropine itself do not exhibit cocaine-
like effects [87], making it unlikely that these non-DAT side effects
are responsible for the behavioral profile of benztropine and its
derivatives. It has also been argued that a slow onset of action
(compared to cocaine) is responsible for the non-classical
behavioral effects of various benztropine-derived atypical DAT
ligands [88,89]. However, a recent study by Li et al. (2011) found
that a number of N-substituted benztropine analogues possessing
rapid onset rates did not induce cocaine-like place preference,
suggesting that a slow onset rate is not required for atypical-like
behavioral effects [20].
Hence, it appears that addictiveness is not a property shared by
all DAT-inhibiting compounds, but instead may be contingent
upon a specific sort of molecular interaction with the DAT
protein. In this study, we compared the nature of modafinil’s
molecular interaction with the dopamine transporter to that of
characterized cocaine-like and atypical uptake inhibitors, employ-
ing a combination of biochemical and computational techniques.
There is ample evidence that different classes of DAT inhibitors
preferentially bind to (or induce upon binding) distinct transporter
Figure 5. Final energy-minimized poses of cocaine-like inhibitors docked at the DAT S1 and S2 sites. Selected binding pocket residues
are labeled and rendered as sticks; bound ligand molecules are highlighted using gray-colored carbon atoms. The distances between the oxygen
atoms of D79 and Y156 are displayed in the lower right of each panel (in yellow). (A, B) b-CFT docked at the S1 (A) and S2 sites (B); binding of b-CFT
at either site disrupts the hydrogen bond between and D79 and Y156 (interatomic distance .3.5 A ˚), indicating that it promotes an open-to-out
conformational state. (C, D) Dexmethylphenidate docked at the respective S1 (C) and S2 sites (D)—similar to CFT, methylphenidate disrupts the D79-
Y156 hydrogen bond upon binding at the S1 site (however, at the S2 site, the D79-Y156 interatomic distance is roughly <3.6 A ˚, hence the effect of
methylphenidate on the integrity of the hydrogen bond is less conclusive).
doi:10.1371/journal.pone.0025790.g005
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the finding that cocaine and benztropine differentially affect the
vulnerability of extracellular-facing DAT cysteine residues towards
reaction with impermeant sulfhydryl reducing reagents, indicating
that these inhibitors stabilize different conformations [40]. In
addition, binding of cocaine-like compounds has been shown to
protect DAT transmembrane arginine residues from covalent
reaction with phenylglyoxal, whereas benztropine-like compounds
failed to affect phenylglyoxal reactivity, further hinting at specific
conformational effects that vary depending upon the structure of
the bound inhibitor [90]. In prior site-directed mutagenesis
studies, we identified two DAT mutants (W84L and D313N) that
bias the conformational equilibrium of the transporter towards the
open-to-out (outward-facing) state [43]. By impeding the transition
from open-to-out to occluded and inward-facing conformations,
the W84L and D313N mutants enhance the binding affinity of
cocaine-like DAT ligands, which bind to and stabilize the
outward-facing state. However, the mutations display either
unchanged or decreased affinity for atypical inhibitors—as well
as DAT substrates (such as dextroamphetamine) and certain
bivalent substrate-like ligands (see [47])—allowing them to be used
as tools to determine whether or not a particular ligand possesses a
cocaine-like mechanism of action. In a previous structure-activity
relationship (SAR) investigation of a variety of structurally unique
DAT inhibitors, we used these two transporter mutants to show
that the presence of a diphenylmethoxy moiety was sufficient (but
not necessary) to engender a given DAT inhibitor molecule with
an atypical binding profile [42]. This particular functional group is
a structural feature common to benztropine, GBR12909 and their
respective 3a-diarylmethoxytropane and 1,4-dialkylpiperazine
derivatives investigated as therapeutics for cocaine addiction
[19]. The fact that modafinil possesses a similar diphenylmethyl
structural moiety—albeit with a sulfinyl functionality in place of
the diphenylmethoxy ether oxygen atom—was a motivation for
investigating its potential conformation-specific interaction with
the DAT.
The data obtained with our outward-biasing DAT mutants are
consistent with the idea that modafinil exhibits an interaction
mode akin to that of the diphenylmethoxy-based inhibitors
benztropine and GBR12909, but different than that of cocaine
and methylphenidate. That is, like other atypical DAT inhibitors,
modafinil preferentially interacts with a ‘‘closed-to-out’’ transport-
Figure 6. Molecular interaction diagrams of cocaine-like inhibitors docked at the S1 and S2 sites. For each panel, the interaction map
depicts DAT residues located within 4.5 A ˚ of the bound inhibitor. As described for Figure 4, the residues are colored based upon their chemical
nature and the most significant DAT/inhibitor interactions are labeled with dotted lines and a symbol depicting the chemistry of the interaction
formed. (A, B) Residue interaction maps for b-CFT bound at the S1 (A) and S2 sites (B). (C, D) Interaction maps for dexmethylphenidate bound at the
S1 (C) and S2 sites (D), respectively. At the S2 site, the interaction pattern of methylphenidate is similar to that of modafinil (compare Figure 6D with
Figure 4B).
doi:10.1371/journal.pone.0025790.g006
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binding assays we performed under conformation-biasing ionic
conditions, as well as our computational modeling data. Amongst
the DAT inhibitors tested, the binding affinity of modafinil was the
least impacted by replacement of extracellular sodium with the
inert cation NMDG, a treatment known to shift the dynamic
equilibrium of the transporter from a predominately open-to-out
state to a more inward-facing one. Binding of the benztropine
analogue JHW007, a potent DAT inhibitor that elicits neither self-
administration nor place preference in behavioral reinforcement
tests, has also been found to be largely insensitive to extracellular
sodium levels [80]. Under these sodium-depleted conditions,
‘‘rescue’’ of the outward-facing transporter state by addition of
10 mMZ n
2+—which interacts with the DAT above the vestibular
S2 site and promotes conformational reorientation from inward-
to outward-facing states—dramatically increased the binding of
cocaine, b-CFT and methylphenidate, but had no effect on
binding of modafinil or the other atypicals (benztropine,
bupropion and GBR12909).
In order to provide a structural context for the binding and
mutagenesis results, we also performed computational studies of
inhibitor interaction with a DAT molecular model. Docking
models of b-CFT and dexmethylphenidate demonstrated that
these inhibitors promote an outward-facing conformation by
breaking a critical D79-Y156 hydrogen bond. By breaking this
interaction, cocaine-like inhibitors appear to impede closure of the
extracellular gating network and therefore prevent the transporter
from transitioning from the open-to-out state to the occluded state.
By contrast, docking models of the atypical inhibitors (R)-modafinil
and (S)-bupropion revealed a preserved D79-Y156 hydrogen
bond, suggesting that binding of either of these inhibitors does not
prevent the DAT from transitioning to a closed-to-out occluded
conformation. It is important to note that the respective effects of
cocaine-like or atypical inhibitors on the D79-Y156 interaction
were maintained when inhibitors were docked in either the central
S1 substrate-binding site or the putative vestibular S2 site. The
exact binding location of uptake inhibitors in NSS proteins has
been intensely debated, particularly following the discovery of
tricyclic binding at the S2 site in the bacterial NSS family member
LeuT. Our docking models, however, suggest that cocaine-like
and atypical inhibitors can exert differential conformational effects
in the transporter protein upon binding at either site. Interestingly,
the D79-Y156 hydrogen bond is also preserved in models of DAT
substrate binding [31,47]. This raises the possibility that, despite
not being translocated across the membrane, atypical inhibitors
like modafinil interact with the DAT in substrate-like manner. It
has been recently proposed that stabilization of an occluded or
inward-facing conformational state, similar to that induced
(transiently) during substrate translocation, underlies the ‘co-
caine-antagonist’ properties of benztropine and other atypical
inhibitors [84]. The rationale being that having a significant
percentage of DATs stabilized in a substrate-like closed confor-
mation will prevent cocaine from interacting with the transporter.
This idea is in fact consistent with the preclinical literature, which
suggests that substrates (such as dextroamphetamine) and atypical
DAT inhibitors (such as modafinil and the benztropines) are more
effective as treatments for cocaine addiction than methylpheni-
date, which preferentially interacts with the same transporter
conformation as cocaine [91].
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